You are crazy. If it is a public company, salary is determined by the board of directors. The CEO does not have the pay himself anything.
All the recent talk and rumors about companies interested in buying Vertex indicates how highly valuable Vertex is in the eye of biotech analysts.
how about biogen buys vertex, and then gilead buys biogen! win win!
these stories are always good for a short term pop but go nowhere
Definitely possible. Biogen has no in-house drivers, their Alzheimer's drug has questions (Lilly's might be better and is ahead in development). Both are located in Boston and they probably could reduce overlap and workforces. Both are working on anti-lingo for MS. Definitely better leadership at Biogen then Vertex.
Papa, note that Leiden also said the first clinical trials using Paroin's ENaC inhibitor with a Vertex corrector/potentiator is using orkambi with Ph 1037 (not 661/kalydeco). In the Q&A he mentioned that it will get Pharion's 1037 approved faster using Orkambi, in combination with PH 1037 because Orkambi is already an FDA approved drug, rather than conducting trials using it with 661/kalydeco. That does not sound like FDA continues to 'doubt' orkambi.
No papa. The residual function arm always had mono which makes sense because kalydeco Denver nof1 showed response mono so they need to show that like others on kalydeco combo will work better...the only difference is residual function isn't on label or currently using kalydeco.
J. Leiden: " The residual function arm always had in it both a placebo and ivacaftor monotherapy compared with 661 plus ivacaftor."
I was not aware of iva mono versus iva+661, to me it seems that FDA asked for that arm, given their doubt on Orkambi
Good call. Most all the senior analysts participated themselves for a change rather than sending surrogates. I expect a positive reaction from the market tomorrow, following the answers given by Leiden and his team, which certainly voiced optimism about the expected revenue growth to be generated by Orkambi,
Leiden clearly articulated Orkambi revenue will be financing the ongoing clinical trials in both CF an non CF drugs in development this year and next. While specific metrics about Orkambi sales during the first few weeks of the launch were not discussed, I did not sense that there was any denials or unexpected delays from health insurers paying for the care of 508dd CF patients in the U.S. who are being prescribed Orkambi since the launch less than one month ago. That's good news for CF patients and VRTX investors